The Limited Times

Now you can see non-English news...

Covid-19: after AstraZeneca's vaccine, Denmark gives up Johnson & Johnson's

2021-05-03T16:43:20.291Z


This decision will slow down the current immunization campaign in this Scandinavian country by four weeks. The benefits of the vaccine do not empo


The first country in Europe to abandon the AstraZeneca vaccine in April, Denmark announced on Monday that it would also drop Johnson & Johnson's vaccine because of possible serious side effects, despite the green lights from the European regulator and the WHO to use it.

“The Danish National Health Authority has concluded that the benefits of using Johnson & Johnson's Covid-19 vaccine do not outweigh the risk of causing a possible side effect, VITT (a very rare type serum injection thrombosis), in people receiving the vaccine.

Therefore, (she) will continue the Danish Covid-19 mass vaccination program without the Johnson & Johnson vaccine, ”she said in a statement.

Four weeks behind in the vaccination campaign

Denmark, which appears with this decision among the first to renounce it in the world, had never authorized the vaccine, marketed in Europe by Janssen, a subsidiary of J&J.

His job or not had been evaluated since mid-April.

This decision will slow down by four weeks the current immunization campaign in the Nordic country, where the epidemic is considered "under control" and where the majority of people at risk and healthcare workers have been vaccinated. Denmark has ordered 8.2 million doses of the vaccine, the first of which were received in mid-April.

According to the latest tally, 11.5% of the 5.8 million Danes are fully vaccinated and 23.4% have received a first injection.

Currently four vaccines are authorized in the EU: Pfizer-BioNTech, Moderna, AstraZeneca and Johnson & Johnson - the latter two under certain age conditions in most European countries.

"It should also be borne in mind that in the future we will first and foremost vaccinate younger and healthy people," said Deputy Director General of the Danish Health Authority, Helene Probst, quoted in the report. communicated.

In April, the US regulator temporarily suspended the use of the Johnson & Johnson vaccine after rare cases of thrombosis.

In Europe, the EMA estimated that it benefited from a favorable benefit / risk ratio despite a "very rare" risk of blood clots.

Source: leparis

All life articles on 2021-05-03

You may like

Trends 24h

Life/Entertain 2024-03-28T17:17:20.523Z

Latest

© Communities 2019 - Privacy

The information on this site is from external sources that are not under our control.
The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.